louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06429254: The Effect of Emotional Freedom Techniques on Pelvic Pain
Official title: Effect of Emotional Freedom Techniques on Pelvic Pain and Quality of Life in Women with Endometriosis: a Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Woman
Pelvic Pain
Keywords: Pelvic pain
Woman
quality of life
Lead sponsor: Karabuk University
Sponsor class: OTHER
First posted: 2024-05-24
Enrollment: 64
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 49
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Pelvic pain caused by endometriosis is a common symptom and reduces women's quality of life.

EFT is a method that can be preferred in pelvic pain due to its ease of use and low cost.

Raising women's awareness for EFT

Detailed description: Pelvic pain caused by endometriosis is a common symptom and reduces women's quality of life. EFT has become widely used in medical and psychological treatment settings in recent years.It is also used as a self-help technique by millions of people every year.EFT is a method that can be preferred in pelvic pain due to its ease of use and low cost.

Eligibility criteria: Inclusion Criteria:

1. Being diagnosed with endometriosis
2. Experiencing pelvic pain
3. Being between the ages of 18-49
4. Those whose symptom complaints are 5 or above on the visual analogue scale

Exclusion Criteria:

1. Patients with known systemic diseases (e.g. hypertension, diabetes, coronary, kidney and liver diseases);
2. Patients with known malignancy;
3. Women in menopause;
4. Having any obstacle to communication

Primary outcomes:
measure: Examining the Effect of Emotional Freedom Technique on Pelvic Pain İn Endometriosis
timeFrame: 1 time per month up to 2 months, Pain will be assessed using the VAS (Visual Analogue Scale). A high score on the scale indicates high pain.
Secondary outcomes:
Other outcomes:
Locations:
city: Edirne
country: Turkey
facility: Trakya University
Study officials:
References:
Clinical trial NCT03743454: Physical Activity Level and Physical Activity Awareness
Official title: Relationship Between Physical Activity Level And Physical Activity Awareness In Young Adults
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Physical Activity
Awareness
Keywords: physical activity level
physical activity awareness
Lead sponsor: Trakya University
Sponsor class: OTHER
First posted: 2018-11-16
Enrollment: 403
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: healthy volunteers

Brief summary: It is important to determine the attitudes and behaviors of individuals towards regular exercise participation in order to direct individuals to physical activity or to implement effective practices related to increasing their participation.

The aim of this study was to determine the awareness of physical activity in young adults, the relationship between physical activity awareness and physical activity level and to investigate the differences between sexes.


Eligibility criteria: Inclusion Criteria:

* healthy young females and males who want to participate to the study
* individuals who have smartphones

Exclusion Criteria:

* have orthopedic, physiologic, psychiatric, neurologic or systemic disorders
* have present medication

Primary outcomes:
measure: Physical Activity Level
timeFrame: After the individuals permission, its taken in the first minute.
measure: Physical Activity Awareness
timeFrame: After they completed the IPAQ-SF, its taken in the sixth minute.
Secondary outcomes:
measure: Number of Steps
timeFrame: After the individuals permission, number of steps will be taken at the end of the first week.
Other outcomes:
Locations:
city: Edirne
country: Turkey
facility: Nimet Sermenli Aydın
Study officials:
References:
Clinical trial NCT04427254: Study of the Sars-Cov2 Neuroinvasiveness - COVID19
Official title: Study of the Sars-Cov2 Neuroinvasiveness - COVID19
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: COVID19
Keywords: Sars-Cov2 neuroinvasiveness
COVID-19 RT-PCR test
Lead sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Sponsor class: NETWORK
First posted: 2020-06-11
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Sars-Cov2 (COVID-19) may invade the CNS inducing neurological diseases such as anosmia, ageusia, encephalitis, ischemic or hemorrhagic stroke. Management of severe neurological complications in COVID-19 patients may require ventricular cerebrospinal fluid drainage and cranial decompression. During surgery, cerebrospinal fluid, meninges and brain parenchyma can be safely removed from the patient. In this study, COVID-19 patients will be evaluated first, for the presence of Sars-Cov2 in the cerebrospinal fluid and/or biopsies and second, for the consequences of Sars-Cov2 neuroinfection in terms of inflammatory and immune responses.


Eligibility criteria: Inclusion Criteria:

* COVID-19 patients requiring an external ventricular drain, a decompressive craniectomy or an intracranial hematoma surgery

Exclusion Criteria:

* Pregnant or lactating women

Primary outcomes:
measure: Percentage of patients with COVID-19 positive samples/biopsies
timeFrame: At the time of the inclusion
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: Fondation A de Rothschild
Study officials:
affiliation: Fondation A. de Rothschild
name: Pierre BOURDILLON, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02626754: A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population
Official title: A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Renal Cell Carcinoma
Keywords: Sunitinib, 2/1 schedule, Renal cell carcinoma
Lead sponsor: Taipei Veterans General Hospital, Taiwan
Sponsor class: OTHER_GOV
First posted: 2015-12-10
Enrollment: 13
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a multi-national, phase II, single arm study to explore the safety/efficacy and potential biomarkers on sunitinib 2/1 schedule for Asian patients with advanced renal cell carcinoma.

Detailed description: Sunitinib 50mg daily on 4/2 dose schedule has been established as standard of care (SOC) for advanced renal cell carcinoma (RCC). However, Asian patients in real world experienced grade III/IV adverse events much more than expected. This multi-national, phase II, single arm study is going to explore more on the safety/efficacy and relevant biomarkers on sunitinib 2/1 dose schedule in Asian people with advanced RCC.

Eligibility criteria: Inclusion Criteria:

* Advanced renal cell carcinoma with histology confirmation
* Grade III/IV AEs happen during first cycle of sunitinib 50mg/day 4 weeks on followed by 2 weeks of rest
* ECOG performance status 0 or 1
* Appropriate vital organ functions

Exclusion Criteria:

* Prior systemic treatment of mRCC
* Patients treated with any neoadjuvant or adjuvant systemic therapy
* Major surgery \<4 weeks or radiation therapy \<2 weeks of starting the study treatment. Prior palliative radiotherapy to metastatic lesion(s) is permitted, provided there is at least one measurable lesion that has not been irradiated
* Pregnant
* Allergic history to sunitinib

Primary outcomes:
measure: Incidence of treatment-emergent adverse events (safety and tolerability)
timeFrame: 24 months
Secondary outcomes:
measure: Objective Response Rate (ORR)
timeFrame: 24 months
measure: progression free survival (PFS)
timeFrame: 24 months
measure: patient reported outcome (PRO)
timeFrame: 24 months
Other outcomes:
measure: single nuclear polymorphism
timeFrame: 24 months
Locations:
city: Kaohsiung
country: Taiwan
facility: Kaohsiung Medical University Chung-HO Memorial Hospital
city: Kaohsiung
country: Taiwan
facility: Kaohsiung Veterans General Hospital
city: Taichung
country: Taiwan
facility: Taichung Veterans General Hospital
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
city: Taipei
country: Taiwan
facility: Taipei Vterans General Hospital
city: Taipei
country: Taiwan
facility: Tri-Service General Hospital
city: Taoyuan City
country: Taiwan
facility: Chang Gung Memorial Hospital, Linkou
Study officials:
affiliation: Taipei Veterans General Hospital, Taiwan
name: Yen-Hwa Chang, M.D. Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00520754: Efficacy and Safety of Levocetirizine for Treatment of Recurrent Cough Associated With Other Allergic Symptoms in Children
Official title: The Efficacy and Safety of Levocetirizine Dihydrochloride Oral Drops Given 0.125 mg/kg b.i.d. During 90 Days in the Treatment of Recurrent Cough Associated With Other Allergic Symptoms, e.g. Wheezing, in Children Aged 1-2 Years.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Cough
Keywords: levocetirizine dihydrochloride Xyzal tablets
Lead sponsor: UCB Pharma
Sponsor class: INDUSTRY
First posted: 2007-08-27
Enrollment: 15
Sex: ALL
Minimum age (years): 2
Maximum age (years): 24
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Efficacy and Safety of Levocetirizine for Treatment of Recurrent Cough Associated With Other Allergic Symptoms in Children


Eligibility criteria: Inclusion Criteria:

* infants from 2 to 24 months both inclusive
* suffering from recurrent cough associated with other allergic symptoms
* hospitalized for respiratory or allergy related problems
* laboratory results within normal ranges
* height and weight between percentile 5 and 95

Exclusion Criteria:

* having taken any of the disallowed medication
* suffering form any disorder
* history of sleep apnea
* having concomitant chronic disease
* known relevant renal, hepatic, cardiac or metabolism dysfunction
* known alcohol or drug addiction, severe psychiatric disease for the parent/guardian

Primary outcomes:
measure: The efficacy based on daily record cards recordings
timeFrame: 90 days
Secondary outcomes:
measure: Safety and pharmacokinetics at 90 days; skin reactivity
Other outcomes:
Locations:
Study officials:
affiliation: UCB Pharma
name: UCB Clinical Trial Call Center
role: STUDY_DIRECTOR
References:
citation: Cranswick N, Turzikova J, Fuchs M, Hulhoven R. Levocetirizine in 1-2 year old children: pharmacokinetic and pharmacodynamic profile. Int J Clin Pharmacol Ther. 2005 Apr;43(4):172-7. doi: 10.5414/cpp43172.
Clinical trial NCT02875054: Camp High 5: Evaluation of the Effect on Upper Limb Function
Official title: Camp High 5 2016: Evaluation of the Effect on Upper Limb Function
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Neurological Injury
Hemiplegia
Lead sponsor: NYU Langone Health
Sponsor class: OTHER
First posted: 2016-08-23
Enrollment: 10
Sex: ALL
Minimum age (years): 2
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Randomized control trial to evaluate uni-manual and bimanual upper limb function as well as compare outcomes of varied cast wear in children with hemiplegic cerebral palsy (CP) following a hybrid camp model of modified constraint induced movement therapy (mCIMT) and hand-arm bimanual intensive training (HABIT).


Eligibility criteria: Inclusion Criteria:

* Participants will range from 2 years to 11 years 11 months of age at time of enrollment. Children under 5 years of age will attend a morning session and children 6 years and older will attend an -Diagnosis: hemiplegia resulting from a neurological Injury
* Manual Ability Classification System or Mini Manual Ability Classification System classification I-III

Exclusion Criteria:

* Botox injection within past 6 months or planned for within 6 months post camp
* Inability to follow commands
* Family unable to commit to daily sessions for 4 weeks
* Unable to tolerate assigned casting protocol (3-24 hours) daily for 4 weeks

Primary outcomes:
measure: Pediatric Motor Activity Log
timeFrame: 6 Months
measure: Assisting Hand Assessment
timeFrame: 6 Months
measure: Melbourne-2
timeFrame: 6 Months
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: New York University School of Medicine
state: New York
Study officials:
affiliation: New York University Medical School
name: Renat Sukhov, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05525754: Computed Tomography-Guided Nasotracheal Intubation Procedure
Official title: Effectiveness of Computed Tomography-Guided Nasotracheal Intubation Procedure on Predicting Tube Advancement Difficulty and Preventing Epistaxis: A Prospective Case-control Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Computed Tomography-guided Nasotracheal Intubation
The Space Where the Tube Will be Passed in the Internal Nasal Valve Region
Keywords: Computed Tomography
epistaxis
Maxillofacial Orthognathic Surgery
Intubation
Lead sponsor: TC Erciyes University
Sponsor class: OTHER
First posted: 2022-09-02
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Sixty health volunteers who went orthognathic surgery

Brief summary: Background: Nasotracheal intubation can lead to severe complications like epistaxis with excessive bleeding. The advancement difficulty of the tube faced during nasal intubation is one of the fundamental causes of this condition. The present study aimed to evaluate the effectiveness of Computed tomography-guided nasotracheal intubation in predicting tube advancement difficulty and preventing epistaxis.

Material and Methods: 60 maxillofacial surgery patients were included in the study. The space where the tube will be passed in the internal nasal valve region was measured horizontally (distance between inferior concha and septum) and vertically (distance between inferior concha and hard palate) by Computed Tomography. The patients were divided into two groups, 'easy' (n=28) or 'difficult' (n=32), according to the effort required to advance the tube through the nasal passage.

ROC analysis was performed, and cut-off values were determined to reveal the distance values at which difficulty may be experienced while advancing the tube. The cut-off values were 1.09 cm and 0.39 cm for the vertically and horizontally distances, respectively.


Eligibility criteria: Inclusion Criteria:

* Aged 18 to 65 who underwent bimaxillary orthognathic surgery
* defined as ASA (American Society of Anesthesiology) I or II

Exclusion Criteria:

* The lack of preoperative CT scans
* airways evaluated and considered difficult by the anesthesiologist
* airways assessed and considered not appropriate for right angle endotracheal (RAE) tube with7.0 mm internal diameter
* history of sinusitis or head trauma
* anticoagulant therapy

Primary outcomes:
measure: Investigation of the relationship between internal nasal valve measurements and nasal advancement of the intubation tube
timeFrame: during intubation procedure
Secondary outcomes:
Other outcomes:
Locations:
city: Kayseri
country: Turkey
facility: SEHER Orbay Yaşlı
Study officials:
affiliation: Erciyes University Faculty of Dentistry
name: SEHER Orbay Yaşlı
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01750554: The Influence of a Bupivacaine Digital Nerve Block Using Rev G.
Official title: The Influence of a Bupivacaine Digital Nerve Block With the New Continuous Sensor (Rev G) on the Accuracy of SpHb Monitoring.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Patients Undergoing Spine Surgery
Keywords: SpHb; hemoglobin monitoring;bupivacaine digital nerve block
Lead sponsor: University of California, San Francisco
Sponsor class: OTHER
First posted: 2012-12-17
Enrollment: 19
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The investigators are proposing to continue investigation to improve the accuracy of the SpHb (continuous hemoglobin monitoring device) by administering an intermediate acting digital nerve block in the finger connected to the SpHb, specifically bupivacaine 0.25% in patients undergoing spine surgery. Bupivacaine is FDA approved and in routine use.

Detailed description: Patients undergoing spine surgery will be randomized to receive (or not) the bupivacaine digital block on the finger attached to the new limited release version of the hemoglobin sensor, RevG. The SpHb reading will be compared to a blood hemoglobin level analyzed in the UCSF Clinical Laboratories.

Eligibility criteria: Inclusion Criteria:

* Male or female 18 years of age or older
* American Society of Anesthesiologists classification 1, 2 or 3
* Scheduled to undergo spine or hip surgery

Exclusion Criteria:

* Pregnant or nursing
* Patients who in the study investigators clinical judgement would not be suitable

Primary outcomes:
measure: SpHb (continuous hemoglobin monitor reading) minus tHb (clinical laboratory determined hemoglobin value).
timeFrame: Intermittent (about hourly) hemoglobin checks throughout the surgery.
Secondary outcomes:
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: University of California, San Francisco
state: California
Study officials:
affiliation: University of California, San Francisco
name: Ronald D Miller, MD, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06693154: Calprotectin Levels in Necrotizing Enterocolitis
Official title: A Comparative Study of Serum and Fecal Calprotectin Levels in Necrotizing Enterocolitis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Necrotising Enterocolitis Neonatal
Keywords: calprotectin
necrotising enterocolitis
Lead sponsor: Ankara Yildirim Beyazıt University
Sponsor class: OTHER
First posted: 2024-11-18
Enrollment: 59
Sex: ALL
Minimum age (years): 3
Maximum age (years): 30
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Newborns admitted to the neonatal intensive care unit (NICU) over a 2-year period, born at or before 32 weeks of gestation with a birth weight of ≤1500 grams, were included in this study.

Brief summary: Necrotizing enterocolitis (NEC) is a serious condition that can affect premature babies, leading to complications like intestinal damage and infection. In our study, we measured specific markers (called calprotectin) in blood and stool to understand how severe NEC is and predict outcomes. We found that these markers were higher in babies with more severe NEC (stage 3), especially in those who needed surgery or sadly did not survive. This information can help doctors detect NEC earlier, understand its severity, and make better decisions for treating affected babies.


Eligibility criteria: Inclusion Criteria:

before 32 weeks of gestation with a birth weight of ≤1500 grams

Exclusion Criteria:

Infants whose families did not provide consent and those with congenital anomalies were excluded.

Primary outcomes:
measure: The predictive value of serum and fecal calprotectin levels in necrotising enterocolitis (NEC)
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Ankara Bilkent City Hospital
Study officials:
affiliation: Ankara Yildirim Beyazıt University
name: Abdullah Kurt
role: STUDY_DIRECTOR
References:
Clinical trial NCT04999254: Osteopathic Consultation in the Emergency Department for Fresh Lateral Ligament Sprain
Official title: Osteopathic Consultation in the Emergency Department for Fresh Lateral Ligament Sprain : a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Ankle Sprains
Lead sponsor: CHU de Reims
Sponsor class: OTHER
First posted: 2021-08-10
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: participants will be assigned to one of two or more groups in parallel for the duration pot the study
Primary purpose: TREATMENT

Brief summary: The study consists in recruiting patients with ankle sprains who visit the emergency department (ED).

Each patient will be tested by an osteopath who we will measure pain, swelling and/or edema, and mobility of the ankle. Patients will be asked to reproduce exercises such as to hold on one foot, to stand on tiptoes...

Then, patients will be divided into two groups. The first group will undergo medical treatment during the ED visit, while the second group will undergo osteopathic treatment.

Three time points will be planned. The first one will be the patient's consultation in the ED where treatment will be carried out according to its assignment, as well as the clinical measures previously described. The second time point will be seven days later (plus or minus three days), where only clinical measurements will be performed. The third time point will be three weeks later (plus or minus three days), when the ankle sprain has consolidated, in order to carry out the clinical measurements again.

These clinical measurements will allow to evaluate the effectiveness of a single osteopathic consultation in the ED. The investigators expect a reduction in immediate pain, and thereafter, a reduction in swelling, and an improved mobility and stability of the ankle.


Eligibility criteria: Inclusion Criteria:

* 18 years and older
* Unilateral sprain
* Stage 1 or 2 sprain
* Recent sprain \< 72 hours
* With or without the presence of edema and/or hematoma
* Receiving prior consultation from an ED physician
* Understanding French
* Agreeing to participate in the study and having signed the consent form
* Apyretic
* Patient affiliated to a social security schem

Exclusion Criteria:

* Fractured foot, tibia, fibula
* Stage 3 ankle sprain
* Operated sprain
* Current use of drugs/alcohol
* Altered mental state
* Chronic ankle injury on the contralateral side
* Person deprived of liberty by a judicial or administrative decision
* Neoplasia
* Any contraindication to osteopathy

Primary outcomes:
measure: Ankle mobility
timeFrame: Week 3
Secondary outcomes:
Other outcomes:
Locations:
city: Reims
country: France
facility: Chu Reims
Study officials:
References: